Cellectis SA (CLLS) has released an update.
Cellectis SA, a biotech firm, has released its unaudited condensed consolidated financial statements for Q1 2024, prepared in accordance with IAS 34. The report includes forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially. The company’s assets and financial position are detailed, indicating changes from the previous year-end.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
